Jane L Roberts
Overview
Explore the profile of Jane L Roberts including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
67
Citations
1211
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Booth M, Booth L, Roberts J, West C, Dent P
Anticancer Drugs
. 2025 Mar;
PMID: 40067790
The biology of GZ17-6.02 alone and more so in combination with either of the standard-of-care agents etoposide or carboplatin killed MYCN overexpressing neuroblastoma (NB) cells is unknown. The methods involved...
2.
Floros K, Fairchild Jr C, Li J, Zhang K, Roberts J, Kurupi R, et al.
Res Sq
. 2024 Jun;
PMID: 38883782
Synovial Sarcoma (SS) is driven by the SS18::SSX fusion oncoprotein and is ultimately refractory to therapeutic approaches. SS18::SSX alters ATP-dependent chromatin remodeling BAF (mammalian SWI/SNF) complexes, leading to the degradation...
3.
Booth L, Roberts J, Spasojevic I, Baker K, Poklepovic A, West C, et al.
Oncotarget
. 2024 May;
15:328-344.
PMID: 38758815
GZ17-6.02 has undergone phase I evaluation in patients with solid tumors (NCT03775525). The RP2D is 375 mg PO BID, with an uveal melanoma patient exhibiting a 15% reduction in tumor...
4.
Floros K, Fairchild C, Li J, Zhang K, Roberts J, Kurupi R, et al.
bioRxiv
. 2024 May;
PMID: 38712286
Synovial Sarcoma (SS) is driven by the SS18::SSX fusion oncoprotein. and is ultimately refractory to therapeutic approaches. SS18::SSX alters ATP-dependent chromatin remodeling BAF (mammalian SWI/SNF) complexes, leading to the degradation...
5.
Booth L, Roberts J, West C, Dent P
Oncotarget
. 2024 Mar;
15:159-174.
PMID: 38441437
GZ17-6.02, a synthetically manufactured compound containing isovanillin, harmine and curcumin, has undergone phase I evaluation in patients with solid tumors (NCT03775525) with a recommended phase 2 dose (RP2D) of 375...
6.
Booth M, Booth L, Roberts J, West C, Dent P
Oncotarget
. 2024 Feb;
15:124-133.
PMID: 38329728
GZ17-6.02, composed of curcumin, harmine and isovanillin, has undergone phase I evaluation in patients with solid tumors (NCT03775525) with an RP2D of 375 mg PO BID. The biology of GZ17-6.02...
7.
Booth L, Roberts J, Poklepovic A, Dent P
Anticancer Drugs
. 2023 Oct;
35(2):177-182.
PMID: 37843030
Herein we discuss multiple pre-clinical projects developed by our group that have been translated into patients at Massey Cancer Center. Our work has used multi-kinase inhibitors, for example, sorafenib, regorafenib...
8.
Booth L, Roberts J, West C, Dent P
Front Oncol
. 2022 Nov;
12:1045459.
PMID: 36408163
GZ17-6.02 is undergoing clinical evaluation in solid tumors and lymphoma. We defined the biology of GZ17-6.02 in prostate cancer cells and determined whether it interacted with the PARP1 inhibitor olaparib...
9.
Dent P, Booth L, Roberts J, Poklepovic A, Martinez J, Cridebring D, et al.
Aging (Albany NY)
. 2022 Oct;
14(20):8221-8242.
PMID: 36227739
We defined the mechanisms by which the chaperone ATPase inhibitor AR12 and the multi-kinase inhibitor neratinib interacted to reduce expression of Tau and amyloid-precursor protein (APP) in microglia and neuronal...
10.
Caillaud M, Thompson D, Toma W, White A, Mann J, Roberts J, et al.
Pharmaceutics
. 2022 Jun;
14(6).
PMID: 35745868
Paclitaxel is widely used in the treatment of various types of solid malignancies. Paclitaxel-induced peripheral neuropathy (PIPN) is often characterized by burning pain, cold, and mechanical allodynia in patients. Currently,...